Eugenia Shmidt

Eugenia Shmidt serves as an Associate Professor in the Department of Gastroenterology, Hepatology, and Nutrition within the School of Medicine at the University of Minnesota. Her academic career demonstrates sustained research productivity with 45 research outputs documented over the past 15 years, showing particular acceleration in recent years with multiple publications in 2024-2025.

Dr. Shmidt's research focuses primarily on inflammatory bowel disease (IBD), with special emphasis on the intersection of IBD with women's health issues. Her work examines pregnancy outcomes, reproductive health, and hormonal factors in IBD patients, as evidenced by her recent publications on twin pregnancies in IBD, hormone replacement therapy effects, and female reproductive outcomes in mouse models of IBD. She also investigates microbiome dysbiosis, treatment optimization, and pharmacokinetics in IBD management.

Analysis of her recent publications reveals a strong trend toward clinical research with practical applications, particularly in optimizing biologic therapies for Crohn's disease and ulcerative colitis. Her work increasingly focuses on sex-specific considerations in IBD management, recognizing the unique challenges faced by women with inflammatory conditions. The research spans basic science (mouse models), clinical trials (OPTIMIZE Trial), and large registry studies.

• Proactive optimization of infliximab using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease (OPTIMIZE Trial, 2021-2026)
• Prospective Blood Sample Collection Study for Product Development in Detecting Colorectal Cancer (2020-2025)
• Women with Inflammatory Bowel Disease and Motherhood: A Prospective Registry (2024-2025)
• Multicenter study of Certolizumab Pegol during pregnancy (2020-2024)
• Long-Term Registry for HUMIRA in Ulcerative Colitis (2019-2020)

Dr. Shmidt serves as Principal Investigator on multiple significant research projects funded by organizations including the Helmsley Charitable Trust, AbbVie, UCB Pharma, and Freenome Holdings. Her collaborative network spans multiple institutions including Beth Israel Deaconess Medical Center, Mount Sinai School of Medicine, and various pharmaceutical partners. Her research contributes to UN Sustainable Development Goals related to good health and well-being, particularly in advancing understanding and treatment of chronic inflammatory conditions.